Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Sara Tolaney MD, MPH

Sara M. Tolaney MD, MPH

Chief, Division of Breast Oncology; Associate Director, Susan F. Smith Center for Women’s Cancers; Senior Physician, Dana-Farber Cancer Institute; Associate Professor of Medicine, Harvard Medical School, Boston, Massachusetts

Dr. Sara Tolaney is the Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute and is internationally recognized for her research and education leadership in breast cancer. She also serves as Associate Director of the Susan F. Smith Center for Women’s Cancers and is a Senior Physician at Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School.

Dr. Tolaney’s research focuses on the development of novel therapies in the treatment of breast cancer and developing more effective and less toxic treatment approaches. She is the author of over 150 peer-reviewed publications with manuscripts included in many prestigious journals such as The New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology, and JAMA Oncology.

Dr. Tolaney received her medical degree from the University of California, San Francisco. She completed her residency in internal medicine at Johns Hopkins and fellowships in hematology and medical oncology at the Dana-Farber Cancer Institute. She obtained her MPH from Harvard School of Public Health.

Disclosures

  • Consultant/advisory role: Novartis; Pfizer; Merck; Eli Lilly; AstraZeneca; Genentech/Roche; Eisai; Sanofi; Bristol Myers Squibb; Seattle Genetics; CytomX Therapeutics; Daiichi Sankyo; Gilead; OncXerna Therapeutics; Zymeworks; Zentalis; Blueprint Medicines; Reveal Genomics; ARC Therapeutics; Infinity Therapeutics; Myovant (company bought out); Zetagen; Umoja Biopharma; Artios Pharma; Menarini/Stemline; Aadi Bioscience; Bayer; Incyte Corporation; Jazz Pharmaceuticals; Natera
  • Research funding: Genentech/Roche; Merck; Exelixis; Pfizer; Lilly; Novartis; Bristol Myers Squibb; Eisai; AstraZeneca; NanoString Technologies; Gilead; Seattle Genetics (now Seagen); Daiichi Sankyo

Recent Contributions to PracticeUpdate:

  1. Outcomes of Palbociclib Rechallenge in Patients With HR+/HER2− Advanced Breast Cancer
  2. 2022 Top Story in Oncology: Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer—DESTINY-Breast04
  3. Trastuzumab Deruxtecan in Patients With HER2-Positive Metastatic Breast Cancer With Brain Metastases
  4. monarcHER: CDK4/6 Inhibition in Patients With HR+, HER2+ Advanced Breast Cancer
  5. AMEERA-3: Amcenestrant in Endocrine-Resistant ER+/HER2− Advanced Breast Cancer
  6. TROPiCS-02: Sacituzumab Govitecan for HR+/HER2− Metastatic Breast Cancer
  7. MONARCH 3: Overall Survival Results of Abemaciclib Plus Nonsteroidal AI for HR+/HER2− Advanced Breast Cancer
  8. ESMO 2022: Recommendations From Dr. Sara Tolaney for Breast Cancer
  9. Fulvestrant or Exemestane Plus Ribociclib After Anti-Estrogen Therapy Plus CDK 4/6 Inhibition for HR+/HER2- Breast Cancer
  10. Sacituzumab Govitecan for Patients With HR+/HER2- Advanced Breast Cancer

Most Read This Week

Recently Updated